FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and relates to (i) combination of an antibody specific for CD38, containing HCDR1 with melphalan sequence, GFTFSSYYMN (SEQ ID NO.: 1), HCDR2 with sequence GISGDPSNTYYADSVKG (SEQ ID NO.: 2), HCDR3 with sequence DLPLVYTGFAY (SEQ ID NO.: 3), LCDR1 with sequence SGDNLRHYYVY (SEQ ID NO.: 4), LCDR2 with sequence GDSKRPS (SEQ ID NO.: 5) and LCDR3 with sequence QTYTGGASL (SEQ ID NO.: 6), and (ii) for the treatment of multiple myeloma. Group of inventions also relates to a method for treating multiple myeloma in an individual, which comprises administration of the said combination.
EFFECT: group of inventions provides a synergistic effect in the treatment of multiple myeloma.
10 cl, 4 ex, 4 dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CD38 ANTIBODY AND LENALTDOMID OR BORTEZOMIB FOR TREATING MULTIPLE MYELOMA AND NHL | 2011 |
|
RU2595839C2 |
| AGENT FOR TREATING MULTIPLE MYELOMA (MM) | 2016 |
|
RU2723047C2 |
| COMBINED THERAPY WITH CD19 ANTIBODY AND NITROGEN MUSTARD | 2012 |
|
RU2625222C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| METHOD OF PREVENTION OR TREATMENT OF PERIPHERAL NEUROPATHY OR PAIN ACCOMPANYING DISEASE IN WHICH PERIPHERAL NEUROPATHY OR ASTROCYTE DISORDER IS IDENTIFIED | 2019 |
|
RU2822199C2 |
| ANTIBODIES TO PROTEIN CD38, AND THEIR USE | 2019 |
|
RU2776795C2 |
| COMBINATION THERAPY WITH ANTI-CD19 ANTIBODY AND A PURINE ANALOG | 2012 |
|
RU2664462C9 |
| ANTIBODY MOLECULES AGAINST APRIL AND APPLICATIONS THEREOF | 2016 |
|
RU2793755C2 |
| ANTIBODIES TO CD38 AND PHARMACEUTICAL COMPOSITIONS BASED THEREON FOR TREATMENT OF AUTOIMMUNE DISEASE MEDIATED BY AUTOANTIBODIES | 2020 |
|
RU2809565C2 |
| COMBINATIONS AND USE THEREOF | 2016 |
|
RU2767063C2 |
